Investor Relations Firm Appointed
Biopure has appointed Sharon Merrill Associates, Inc. as its strategic communications firm to support its investor relations and corporate communications efforts. Sharon Merrill Associates is based in Boston.
Ernst & Young LLP has advised Biopure that they are not standing for reappointment for the fiscal year 2008 audit.
The U.S. FDA has announced a public workshop entitled: Hemoglobin Based
Oxygen Carriers: Current Status and Future Directions, on April 29 and 30,
2008. Biopure has been asked to present at the workshop.
Usage of Hemopure in South Africa is continuing to increase.
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. Biopure has applied
in the United Kingdom for regulatory approval of a proposed orthopedic
surgical anemia indication. The company is developing Hemopure for other
indications and is supporting the U.S. Navy's government-funded efforts to
develop a potential out-of-hospital trauma indication. Biopure's veterinary
product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the
only oxygen therapeutic approved for marketing by both the U.S. Food and
Drug Administration and the European Commission, is indicated for the
treatment of anemia in dogs. Biopure has sold approximately 197,000 units
of Oxyglobin since it first began to mar
|SOURCE Biopure Corporation|
Copyright©2008 PR Newswire.
All rights reserved